Spinosad Shortage: What Providers and Prescribers Need to Know in 2026

Spinosad Shortage: What Providers and Prescribers Need to Know in 2026

As a healthcare provider treating head lice or scabies, you may have patients reporting difficulty filling prescriptions for Spinosad (Natroba). This briefing covers the current supply situation, prescribing implications, cost and access considerations, and tools that can help your patients locate this medication.

Provider Briefing: Current Supply Status

As of early 2026, Spinosad is not on the FDA's official drug shortage list. There are no active manufacturing disruptions or supply chain issues affecting the product. ParaPRO, LLC — the manufacturer of brand Natroba — continues to produce the medication, and generic Spinosad topical suspension 0.9% is also available on the market.

However, functional access barriers persist. Spinosad is a specialty topical antiparasitic with relatively low prescription volume compared to chronic-use medications. As a result, many retail pharmacies — particularly large chain pharmacies — do not maintain routine stock. Patients frequently encounter "not in stock" responses that can delay treatment by 1 to 5 business days, depending on ordering and insurance authorization timelines.

Timeline of Key Developments

• January 2011: FDA approves Natroba (Spinosad) topical suspension 0.9% for head lice in patients 4 years and older
• April 2021: FDA approves expanded indication for scabies in patients 4 years and older — the first new FDA-approved scabies treatment in decades
• 2022: FDA updates age indication for head lice to 6 months and older
• 2023-2024: Generic Spinosad topical suspension enters the market
• 2025-2026: Generic availability improves but pharmacy stocking remains inconsistent

Prescribing Implications

Spinosad offers distinct clinical advantages that make it a valuable treatment option:

For Head Lice

• Single 10-minute application with no nit combing required
• Effective against Permethrin-resistant head lice — an increasingly relevant consideration as resistance rates rise across the U.S.
• FDA-approved for patients 6 months and older
• Can be repeated after 7 days if live lice are still present

For Scabies

• Only FDA-approved prescription product to meet the FDA's "complete cure" criteria for scabies
• Single full-body application from neck to soles of feet
• Applied to dry skin, allowed to dry for 10 minutes, left on for at least 6 hours
• FDA-approved for patients 4 years and older

These characteristics make Spinosad particularly appropriate for patients with:

• Treatment-resistant head lice (failed Permethrin or Pyrethrins)
• Scabies requiring a single-application cure
• Adherence challenges that make multi-step or multi-day regimens difficult
• Young children (for head lice, down to 6 months of age)

For detailed prescribing information, refer to the Spinosad uses and dosage guide and the mechanism of action overview.

Availability Picture in 2026

The practical availability landscape for Spinosad breaks down as follows:

Brand Natroba

• Available but not routinely stocked at most retail pharmacies
• Can be ordered by pharmacies from wholesalers, typically arriving in 1 to 2 business days
• Retail price: approximately $400 per 120 mL bottle

Generic Spinosad

• Available and increasingly carried by pharmacies
• Retail price: approximately $285 per bottle
• With discount coupons (GoodRx, SingleCare): as low as $121

Independent Pharmacies

• Generally more responsive to special-order requests
• May offer more competitive cash pricing
• Worth recommending to patients who are encountering stocking issues at chain pharmacies

Cost and Access Considerations

Cost remains a significant barrier for many patients:

Insurance Coverage

Most commercial insurance plans and Medicaid programs cover Spinosad, but with restrictions:

• Prior authorization is widely required — particularly for the brand product
• Step therapy is common: patients must typically try and fail Permethrin before Spinosad is approved
• Some plans may cover generic Spinosad at a lower tier than brand Natroba
• Medicare coverage varies by plan but is generally available for Part D beneficiaries

Out-of-Pocket Costs

For uninsured or underinsured patients:

• Encourage use of discount card programs (GoodRx, SingleCare, RxSaver) to reduce the generic price from ~$285 to as low as $121
• NeedyMeds.org and RxAssist.org may list additional assistance programs
• ParaPRO's website (natroba.com) provides savings information

For comprehensive savings strategies, direct patients to our guide on saving money on Spinosad.

Tools and Resources for Your Practice

Several tools can help streamline the prescribing and fulfillment process:

Medfinder for Providers

Medfinder allows providers to check real-time pharmacy inventory for Spinosad in their patient's area. This can be used proactively — before writing the prescription — to identify a pharmacy that has the medication in stock, reducing fill delays.

Proactive Prior Authorization

When prescribing Spinosad, consider:

• Documenting failed first-line therapy (Permethrin) clearly in the chart
• Submitting prior authorization at the time of prescribing, not after the pharmacy rejection
• Including clinical rationale (e.g., treatment resistance, single-application adherence benefit, FDA scabies indication)

Patient Education Materials

Direct patients to these resources for self-service support:

• How to find Spinosad in stock near you
• Spinosad side effects: what to expect
• Spinosad drug interactions

Looking Ahead

Several factors may improve Spinosad access over the coming months:

• Increasing generic penetration: As more pharmacies adopt the generic version, both availability and pricing should improve
• Insurance formulary updates: Generic availability often leads to more favorable formulary placement and reduced prior authorization requirements
• Growing scabies awareness: The 2021 scabies indication expanded the patient population, which may incentivize pharmacies to stock Spinosad more routinely

Providers who proactively address availability and cost at the point of prescribing — rather than relying on patients to navigate these barriers alone — will see better treatment outcomes and higher patient satisfaction.

Final Thoughts

Spinosad (Natroba) remains a clinically valuable tool for treating head lice and scabies, particularly in resistant or complex cases. While not in formal shortage, real-world access barriers related to pharmacy stocking, insurance requirements, and cost continue to affect patients.

By using tools like Medfinder for Providers, proactively managing prior authorization, and directing patients to savings resources, you can help ensure your patients get the treatment they need without unnecessary delays.

For more provider-focused guidance, see our companion article: How to help your patients find Spinosad in stock.